Catalytic

Co-targeting the EGFR and PI3K/Akt pathway to overcome therapeutic resistance in head and neck squamous cell carcinoma: What about autophagy?

Authors: Hannah Zaryouh, Jinthe Van Loenhout, Marc Peeters, Jan Baptist,Vermorken, Filip Lardon, An Wouters

Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma. The Epidermal Growth Factor Receptor (EGFR) is overexpressed in the majority of Head and Neck Squamous Cell Carcinomas (HNSCC). This triggered the development of multiple anti.. Read More»

Genet. Mol. Res. 20(6):